vs

Side-by-side financial comparison of John Marshall Bancorp, Inc. (JMSB) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

NEKTAR THERAPEUTICS is the larger business by last-quarter revenue ($21.8M vs $16.8M, roughly 1.3× John Marshall Bancorp, Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -165.4%, a 201.8% gap on every dollar of revenue. Over the past eight quarters, John Marshall Bancorp, Inc.'s revenue compounded faster (15.3% CAGR vs 0.4%).

John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

JMSB vs NKTR — Head-to-Head

Bigger by revenue
NKTR
NKTR
1.3× larger
NKTR
$21.8M
$16.8M
JMSB
Higher net margin
JMSB
JMSB
201.8% more per $
JMSB
36.3%
-165.4%
NKTR
Faster 2-yr revenue CAGR
JMSB
JMSB
Annualised
JMSB
15.3%
0.4%
NKTR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
JMSB
JMSB
NKTR
NKTR
Revenue
$16.8M
$21.8M
Net Profit
$6.1M
$-36.1M
Gross Margin
Operating Margin
-126.9%
Net Margin
36.3%
-165.4%
Revenue YoY
-25.3%
Net Profit YoY
26.8%
-596.9%
EPS (diluted)
$0.43
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JMSB
JMSB
NKTR
NKTR
Q1 26
$16.8M
Q4 25
$16.4M
$21.8M
Q3 25
$16.3M
$11.8M
Q2 25
$15.4M
$11.2M
Q1 25
$14.6M
$10.5M
Q4 24
$14.3M
$29.2M
Q3 24
$13.8M
$24.1M
Q2 24
$12.6M
$23.5M
Net Profit
JMSB
JMSB
NKTR
NKTR
Q1 26
$6.1M
Q4 25
$5.9M
$-36.1M
Q3 25
$5.4M
$-35.5M
Q2 25
$5.1M
$-41.6M
Q1 25
$4.8M
$-50.9M
Q4 24
$4.8M
$7.3M
Q3 24
$4.2M
$-37.1M
Q2 24
$3.9M
$-52.4M
Gross Margin
JMSB
JMSB
NKTR
NKTR
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Operating Margin
JMSB
JMSB
NKTR
NKTR
Q1 26
Q4 25
47.4%
-126.9%
Q3 25
42.2%
-268.6%
Q2 25
42.7%
-324.2%
Q1 25
42.4%
-425.8%
Q4 24
42.5%
49.2%
Q3 24
38.8%
-142.4%
Q2 24
39.7%
-211.9%
Net Margin
JMSB
JMSB
NKTR
NKTR
Q1 26
36.3%
Q4 25
36.2%
-165.4%
Q3 25
33.2%
-301.3%
Q2 25
33.1%
-372.2%
Q1 25
32.9%
-486.4%
Q4 24
33.3%
24.9%
Q3 24
30.7%
-153.6%
Q2 24
30.9%
-222.9%
EPS (diluted)
JMSB
JMSB
NKTR
NKTR
Q1 26
$0.43
Q4 25
$0.41
$-4.67
Q3 25
$0.38
$-1.87
Q2 25
$0.36
$-2.95
Q1 25
$0.34
$-0.24
Q4 24
$0.33
$-2.07
Q3 24
$0.30
$-2.66
Q2 24
$0.27
$-3.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JMSB
JMSB
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$150.2M
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$268.1M
$89.8M
Total Assets
$2.4B
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JMSB
JMSB
NKTR
NKTR
Q1 26
$150.2M
Q4 25
$130.0M
$15.1M
Q3 25
$163.6M
$41.0M
Q2 25
$116.9M
$43.0M
Q1 25
$169.1M
$38.9M
Q4 24
$122.5M
$44.3M
Q3 24
$177.2M
$30.1M
Q2 24
$182.6M
$27.9M
Total Debt
JMSB
JMSB
NKTR
NKTR
Q1 26
Q4 25
$80.9M
Q3 25
$80.9M
Q2 25
$80.8M
Q1 25
$80.8M
Q4 24
$80.8M
Q3 24
$80.8M
Q2 24
$24.7M
Stockholders' Equity
JMSB
JMSB
NKTR
NKTR
Q1 26
$268.1M
Q4 25
$265.6M
$89.8M
Q3 25
$259.7M
$85.1M
Q2 25
$253.7M
$-24.2M
Q1 25
$253.0M
$13.7M
Q4 24
$246.6M
$60.7M
Q3 24
$243.1M
$48.9M
Q2 24
$235.3M
$79.7M
Total Assets
JMSB
JMSB
NKTR
NKTR
Q1 26
$2.4B
Q4 25
$2.3B
$280.4M
Q3 25
$2.3B
$301.3M
Q2 25
$2.3B
$207.5M
Q1 25
$2.3B
$256.2M
Q4 24
$2.2B
$303.9M
Q3 24
$2.3B
$308.0M
Q2 24
$2.3B
$343.3M
Debt / Equity
JMSB
JMSB
NKTR
NKTR
Q1 26
Q4 25
0.30×
Q3 25
0.31×
Q2 25
0.32×
Q1 25
0.32×
Q4 24
0.33×
Q3 24
0.33×
Q2 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JMSB
JMSB
NKTR
NKTR
Operating Cash FlowLast quarter
$-65.0M
Free Cash FlowOCF − Capex
$-65.0M
FCF MarginFCF / Revenue
-298.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JMSB
JMSB
NKTR
NKTR
Q1 26
Q4 25
$22.6M
$-65.0M
Q3 25
$1.2M
$-48.8M
Q2 25
$7.5M
$-45.7M
Q1 25
$7.0M
$-49.1M
Q4 24
$17.3M
$-46.2M
Q3 24
$1.4M
$-43.9M
Q2 24
$10.2M
$-37.7M
Free Cash Flow
JMSB
JMSB
NKTR
NKTR
Q1 26
Q4 25
$22.0M
$-65.0M
Q3 25
$1.2M
$-48.9M
Q2 25
$7.4M
$-45.8M
Q1 25
$6.6M
$-49.1M
Q4 24
$16.8M
$-46.6M
Q3 24
$1.3M
$-44.6M
Q2 24
$10.1M
$-37.9M
FCF Margin
JMSB
JMSB
NKTR
NKTR
Q1 26
Q4 25
134.7%
-298.0%
Q3 25
7.3%
-414.5%
Q2 25
47.8%
-409.6%
Q1 25
45.3%
-469.0%
Q4 24
116.9%
-159.9%
Q3 24
9.5%
-184.9%
Q2 24
80.1%
-161.3%
Capex Intensity
JMSB
JMSB
NKTR
NKTR
Q1 26
Q4 25
3.4%
0.1%
Q3 25
0.2%
1.0%
Q2 25
1.0%
0.3%
Q1 25
2.3%
0.0%
Q4 24
3.4%
1.6%
Q3 24
0.8%
2.8%
Q2 24
0.4%
0.8%
Cash Conversion
JMSB
JMSB
NKTR
NKTR
Q1 26
Q4 25
3.82×
Q3 25
0.23×
Q2 25
1.48×
Q1 25
1.45×
Q4 24
3.61×
-6.36×
Q3 24
0.33×
Q2 24
2.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JMSB
JMSB

Net Interest Income$16.5M98%
Noninterest Income$284.0K2%

NKTR
NKTR

Segment breakdown not available.

Related Comparisons